Toxicological safety evaluation of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar despite differing plasmid backbones or gene-inserts.
The Vaccine Research Center has developed a number of vaccine candidates for different diseases/infectious agents (HIV-1, Severe Acute Respiratory Syndrome virus, West Nile virus, and Ebola virus, plus a plasmid cytokine adjuvant-IL-2/Ig) based on a DNA plasmid vaccine platform. To support the clinical development of each of these vaccine candidates, preclinical studies were performed to screen for potential toxicities (intrinsic and immunotoxicities). All treatment-related toxicities identified in these repeated-dose toxicology studies have been confined primarily to the sites of injection and seem to be the result of both the delivery method (as they are seen in both control and treated animals) and the intended immune response to the vaccine (as they occur with greater frequency and severity in treated animals). Reactogenicity at the site of injection is generally seen to be reversible as the frequency and severity diminished between doses and between the immediate and recovery termination time points. This observation also correlated with the biodistribution data reported in the companion article (Sheets et al., 2006), in which DNA plasmid vaccine was shown to remain at the site of injection, rather than biodistributing widely, and to clear over time. The results of these safety studies have been submitted to the Food and Drug Administration to support the safety of initiating clinical studies with these and related DNA plasmid vaccines. Thus far, standard repeated-dose toxicology studies have not identified any target organs for toxicity (other than the injection site) for our DNA plasmid vaccines at doses up to 8 mg per immunization, regardless of disease indication (i.e., expressed gene-insert) and despite differences (strengths) in the promoters used to drive this expression. As clinical data accumulate with these products, it will be possible to retrospectively compare the safety profiles of the products in the clinic to the results of the repeated-dose toxicology studies, in order to determine the utility of such toxicology studies for signaling potential immunotoxicities or intrinsic toxicities from DNA vaccines. These data build on the biodistribution studies performed (see companion article, Sheets et al., 2006) to demonstrate the safety and suitability for investigational human use of DNA plasmid vaccine candidates for a variety of infectious disease prevention indications.
Sheets
Rebecca L
RL
U.S. Public Health Service, Vaccine Production Program, NIH/NIAID/Vaccine Research Center, Bethesda, Maryland 20892-7628, USA. rsheets@niaid.nih.gov
Stein
Judith
J
Manetz
T Scott
TS
Andrews
Charla
C
Bailer
Robert
R
Rathmann
John
J
Gomez
Phillip L
PL
D000163:Acquired Immunodeficiency Syndrome / Q000235:genetics / Q000276:immunology / Q000517:prevention & control; D000818:Animals; D029043:Ebolavirus / Q000235:genetics / Q000276:immunology; D005260:Female; D005814:Genes, Viral; D015497:HIV-1 / Q000235:genetics / Q000276:immunology; D019142:Hemorrhagic Fever, Ebola / Q000235:genetics / Q000276:immunology / Q000517:prevention & control; D007273:Injections, Intramuscular; D008297:Male; D010957:Plasmids; D011401:Promoter Regions, Genetic; D011817:Rabbits; D045169:Severe Acute Respiratory Syndrome / Q000235:genetics / Q000276:immunology / Q000517:prevention & control; D014018:Tissue Distribution; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000633:toxicity*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000633:toxicity*; D014901:West Nile Fever / Q000235:genetics / Q000276:immunology / Q000517:prevention & control; D014902:West Nile virus / Q000235:genetics / Q000276:immunology
D019444:Vaccines, DNA; D014765:Viral Vaccines